Recent evidence suggests that even in treated infections, human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication may continue in lymph nodes (LN), (1, 2). Furthermore, the immune pressure exerted by NK cells upon this virus is demonstrated by mutations in HIV that are associated with expression of certain NK cell receptors (3). NK cell activation by HIV-infected cells is dependent on Nefmediated downregulation of major histocompatibility complex (MHC) class I surface expression, which decreases availability of these ligands for inhibitory NK cell receptors (4, 5). In addition to this lessening of inhibition, Vpr-mediated upregulation of UL16-binding proteins (ULBPs) 1, 2, and 3 on HIV-infected cells can trigger lysis through the activating NKG2D receptor (6, 7). NK cells activated by immunodeficiency virus-infected cells can inhibit viral replication by lysis of infected cells (8) and secretion of chemokines CCL3, CCL4, and CCL5, which inhibit HIV entry (9).Infection with HIV or simian immunodeficiency virus (SIV) in turn affects NK cell distribution and function. During acute HIV infection, the cytotoxic CD56 dim CD16 ϩ NK cell subset expands in peripheral blood mononuclear cells (PBMC), whereas cytokine-producing CD56 bright NK cells contract in this compartment (10). Likewise, in SIV infection of rhesus macaques, CD16 ϩ NK cells become more prevalent in the periphery, while CD56 ϩ NK cells accumulate in the gut and acquire a more cytotoxic phenotype (11,12). In HIV infection, further viral replication causes the rise of abnormal CD56 Ϫ CD16 ϩ NK cells that are anergic, exhibiting low CD107a degranulation responses (10, 13). Functional impairment of NK cells during progressive HIV or SIV infection also includes diminished antibody-dependent cellular cytotoxic